Home › All Companies › AURX › Current Report

Nuo Therapeutics, Inc. (AURX) — Current Report

AI-Powered SEC Filing Analysis

← All AURX filings
Latest Current Report Filed: 2026-01-26

Key Insights

  • Nuo Therapeutics secured a $1.6 million loan facility, with $1 million funded immediately and an additional $600,000 available upon request, to be used for general working capital purposes.
  • Two of Nuo Therapeutics' major shareholders, Scott M. Pittman and Paul Anthony Jacobs, participated in the loan as lenders, indicating their continued support for the company.
  • The loan agreement includes various prepayment terms, including mandatory prepayment upon certain events such as an equity financing of at least $5 million or a change in control.
Sentiment: Positive Significance: 7/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-01-26. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Nuo Therapeutics, Inc.

Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.